Hutchmed Limited discovered novel therapy amdizalisib (HMPL-689), for the treatment of relapsed or refractory follicular lymphoma (“FL”).
Amdizalisib is an inhibitor for PI3Kδ (phosphoinositide 3-kinase delta),a lipid kinase which helps in controlling the activation of several important signaling proteins. Moreover, when antigen is binded to B-cell receptors, PI3Kδ activates through the Lyn and Syk signaling cascade.
Novel Amdizalisib (HMPL-689), is an oral inhibitor targetingthe isoform PI3Kδ. Some of its properties include good oral absorption,signifying low risk of drug accumulation and drug-to-drug interaction, moderate tissue distribution and low clearance in preclinical PK studies.
The abnormal action of B-cell receptor signaling leads to the growth of B-cell type hematological cancers, resulting in 85% of all NHL cases. Hence, PI3Kδ is the promising drug considered for the treatment of hematologic cancers.
In US and Europe regions, Amdizalisib is being evaluated in an ongoing Phase I/Ib studyin patients with relapsed or refractory NHL.
Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) grants Breakthrough Therapy Designation (“BTD”) foramdizalisib (HMPL-689)to treat relapsed or refractory follicular lymphoma.
